| Literature DB >> 30842517 |
Jan Zmuc1, Gorana Gasljevic1, Gregor Sersa1, Ibrahim Edhemovic1, Nina Boc1, Alenka Seliskar2, Tanja Plavec2, Maja Brloznik2, Nina Milevoj2, Erik Brecelj1, Bor Kos3, Jani Izlakar1, Tomaz Jarm3, Marko Snoj1, Marina Stukelj2, Damijan Miklavcic3, Maja Cemazar4.
Abstract
The first clinical studies on the use of electrochemotherapy to treat liver tumours that were not amenable to surgery or thermal ablation techniques have recently been published. However, there is still a lack of data on the effects of electrochemotherapy on normal liver tissue. Therefore, we designed a translational animal model study to test whether electrochemotherapy with bleomycin causes clinically significant damage to normal liver tissue, with emphasis on large blood vessels and bile ducts. We performed electrochemotherapy with bleomycin or delivered electric pulses alone using a potentially risky treatment strategy in eight pigs. Two and seven days after treatment, livers were explanted, and histological analysis was performed. Blood samples were collected before treatment and again before euthanasia to evaluate blood biomarkers of liver function and systemic inflammatory response. We found no thrombosis or other clinically significant damage to large blood vessels and bile ducts in the liver. No clinical or laboratory findings suggested impaired liver function or systemic inflammatory response. Electrochemotherapy with bleomycin does not cause clinically significant damage to normal liver tissue. Our study provides further evidence that electrochemotherapy with bleomycin is safe for treatment of patients with tumours near large blood vessels in the liver.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30842517 PMCID: PMC6403381 DOI: 10.1038/s41598-019-40395-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Gross examination of explanted livers. White arrows point to where variable linear (a) and fixed hexagonal (b) geometry electrodes were inserted and electric pulses were applied. All scales in cm.
Figure 2Representative images of the acute/subacute changes two days after the treatment. Zones 1 and 2 surround the electrode, Zone 3 represents partially damaged livery parenchyma, and Zone 4 represents intact liver parenchyma. The size of the zones depended on the type of the electrodes and number of pulses used. (a) Variable linear geometry electrodes (animal number 3; image shows the changes parallel to the insertion of the needles). (b) Numerical model showing the electric field distribution in the liver parenchyma between the two needle electrodes. Due to the angled cutting plane, the electrodes on image b are visible for only 5 mm. The thick black lines mark the threshold for irreversible electroporation. (c) Fixed hexagonal geometry electrodes (animal number 2; image shows the changes perpendicular to the insertion of the needles). (d) Numerical model showing the electric field distribution in the hexagonal needle array. The thick black lines mark the threshold for irreversible electroporation.
Figure 3Close-up of the acute changes in Zones 1 and 2. (a) Central cavity caused by the insertion of the electrode (Zone 1, black star) filled with blood and coagulation necrosis (Zone 2, black arrow). (b) Damaged liver parenchyma (black stars) with ghost hepatocytes with pyknotic nuclei and partially damaged small venules (blue arrows) containing a fibrin thrombus (F). Arterioles are intact (red arrows). (c,d) Complete necrosis (black star) adjacent to the lumen (L) of a large hepatic vein. The vessel wall is partially damaged, with missing tunica muscularis (blue arrow), but no thrombosis is present.
Figure 4Close-up of the acute changes in Zone 3. (a) Damaged centri- and midlobular areas (red arrow) with the vital peripheral parts of the lobus (black arrow). (b) Fibrin thrombus (black arrow) in a damaged arteriole. (c) Undamaged bile duct epithelium (green arrow) near the coagulative necrosis.
Figure 5Representative image of the chronic changes seven days after treatment. (a) Three distinct zones were observed (Zone A of coagulation necrosis, Zone B of fibrotic proliferation, and Zone C of normal liver parenchyma with regenerating hepatocytes). (b) Residual necrosis (black star) with ingrowth of the granulation tissue in Zone A. Fibrotic changes (blue stars) with the proliferation of small bile ducts (green arrows) in Zone B. (c) Multinuclear regenerative hepatocytes (black arrows) were seen in Zone C on the margins of fibrotic changes (blue star), while the rest represent undamaged parenchyma (Pa).
Experimental animal weights, treatment data and laboratory results.
| Animal number | Weight | Time to euthanasia | Electrode type | Treatment | ALT activity (IU/L)a | |
|---|---|---|---|---|---|---|
| 1 | 30 kg | 2 days | Variable linear | ECT with bleomycin | 57.6 |
|
| 2 | 32 kg | 2 days | Fixed hexagonal | ECT with bleomycin | 48.3 |
|
| 3 | 30 kg | 2 days | Variable linear | Electric pulses | 26.9 | 41 |
| 4b | 33 kg | 7 days | Variable linear | ECT with bleomycin | 38.3 |
|
| 5b | 28.7 kg | 7 days | Variable linear | ECT with bleomycin | 43.8 |
|
| 6b | 32 kg | 7 days | Variable linear | ECT with bleomycin | 41 |
|
| 7 | 30 kg | 7 days | Fixed hexagonal | ECT with bleomycin | 30.5 |
|
| 8 | 30.5 kg | 7 days | Variable linear | Electric pulses | 39.7 |
|
Values in normal text are before treatment, and the values in italics are before euthanasia.
aStatistically significant difference, P = 0.005.
bWe consider the use of two variable linear electrodes to be the riskiest ECT treatment strategy due to the high voltages used, therefore we repeated the experiment on three test animals.
Figure 6Electrode positioning. (a) Insertion sites of variable linear geometry needle electrodes are marked with electrocautery on an explanted pig liver (VC - caudal vena cava, HV - middle left hepatic vein, PV - left portal vein, Pa - peripheral liver parenchyma). (b) Intraoperative ultrasound image of one of the variable linear geometry needle electrodes (white arrow) inserted into the lumen (L) of the caudal vena cava during the treatment.